175 related articles for article (PubMed ID: 19402031)
21. Prevalence and risk factors associated with antiretroviral resistance in HIV-1-infected children.
Delaugerre C; Warszawski J; Chaix ML; Veber F; Macassa E; Buseyne F; Rouzioux C; Blanche S
J Med Virol; 2007 Sep; 79(9):1261-9. PubMed ID: 17607781
[TBL] [Abstract][Full Text] [Related]
22. Increased rate of prematurity associated with antenatal antiretroviral therapy in a German/Austrian cohort of HIV-1-infected women.
Grosch-Woerner I; Puch K; Maier RF; Niehues T; Notheis G; Patel D; Casteleyn S; Feiterna-Sperling C; Groeger S; Zaknun D;
HIV Med; 2008 Jan; 9(1):6-13. PubMed ID: 18199167
[TBL] [Abstract][Full Text] [Related]
23. Body fat changes among antiretroviral-naive patients on PI- and NNRTI-based HAART in the Swiss HIV cohort study.
Young J; Rickenbach M; Weber R; Furrer H; Bernasconi E; Hirschel B; Tarr PE; Vernazza P; Battegay M; Bucher HC
Antivir Ther; 2005; 10(1):73-81. PubMed ID: 15751765
[TBL] [Abstract][Full Text] [Related]
24. Antiretroviral therapy exposure and incidence of diabetes mellitus in the Women's Interagency HIV Study.
Tien PC; Schneider MF; Cole SR; Levine AM; Cohen M; DeHovitz J; Young M; Justman JE
AIDS; 2007 Aug; 21(13):1739-45. PubMed ID: 17690572
[TBL] [Abstract][Full Text] [Related]
25. An updated systematic overview of triple combination therapy in antiretroviral-naive HIV-infected adults.
Bartlett JA; Fath MJ; Demasi R; Hermes A; Quinn J; Mondou E; Rousseau F
AIDS; 2006 Oct; 20(16):2051-64. PubMed ID: 17053351
[TBL] [Abstract][Full Text] [Related]
26. Effects of highly active antiretroviral therapy on paediatric metabolite levels.
Rhoads MP; Smith CJ; Tudor-Williams G; Kyd P; Walters S; Sabin CA; Lyall EG
HIV Med; 2006 Jan; 7(1):16-24. PubMed ID: 16313288
[TBL] [Abstract][Full Text] [Related]
27. Acute pancreatitis associated with different combination therapies in patients infected with human immunodeficiency virus.
Guo JJ; Jang R; Louder A; Cluxton RJ
Pharmacotherapy; 2005 Aug; 25(8):1044-54. PubMed ID: 16207094
[TBL] [Abstract][Full Text] [Related]
28. Long-term effectiveness of highly active antiretroviral therapy on the survival of children and adolescents with HIV infection: a 10-year follow-up study.
Patel K; Hernán MA; Williams PL; Seeger JD; McIntosh K; Van Dyke RB; Seage GR;
Clin Infect Dis; 2008 Feb; 46(4):507-15. PubMed ID: 18199042
[TBL] [Abstract][Full Text] [Related]
29. Positive virological outcome after lopinavir/ritonavir salvage therapy in protease inhibitor-experienced HIV-1-infected children: a prospective cohort study.
Resino S; Bellón JM; Ramos JT; Gonzalez-Rivera M; de José MI; González MI; Gurbindo D; Mellado MJ; Cabrero E; Muñoz-Fernández MA
J Antimicrob Chemother; 2004 Nov; 54(5):921-31. PubMed ID: 15472006
[TBL] [Abstract][Full Text] [Related]
30. The incidence rate of HIV type-1 drug resistance in patients on antiretroviral therapy: a nationwide population-based Danish cohort study 1999-2005.
Audelin AM; Lohse N; Obel N; Gerstoft J; Jørgensen LB
Antivir Ther; 2009; 14(7):995-1000. PubMed ID: 19918103
[TBL] [Abstract][Full Text] [Related]
31. The metabolic syndrome, an epidemic among HIV-infected patients on HAART.
Jevtović DJ; Dragović G; Salemović D; Ranin J; Djurković-Djaković O
Biomed Pharmacother; 2009 Jun; 63(5):337-42. PubMed ID: 18996676
[TBL] [Abstract][Full Text] [Related]
32. Preliminary outcomes of a paediatric highly active antiretroviral therapy cohort from KwaZulu-Natal, South Africa.
Reddi A; Leeper SC; Grobler AC; Geddes R; France KH; Dorse GL; Vlok WJ; Mntambo M; Thomas M; Nixon K; Holst HL; Karim QA; Rollins NC; Coovadia HM; Giddy J
BMC Pediatr; 2007 Mar; 7():13. PubMed ID: 17367540
[TBL] [Abstract][Full Text] [Related]
33. Long-term effects of highly active antiretroviral therapy in pretreated, vertically HIV type 1-infected children: 6 years of follow-up.
Resino S; Resino R; Micheloud D; Gurbindo Gutiérrez D; Léon JA; Ramos JT; Ciria L; de José I; Mellado J; Muñoz-Fernández A;
Clin Infect Dis; 2006 Mar; 42(6):862-9. PubMed ID: 16477566
[TBL] [Abstract][Full Text] [Related]
34. Cerebrovascular ischemic events in HIV-1-infected patients receiving highly active antiretroviral therapy: incidence and risk factors.
Corral I; Quereda C; Moreno A; Pérez-Elías MJ; Dronda F; Casado JL; Muriel A; Masjuán J; Alonso-de-Leciñana M; Moreno S
Cerebrovasc Dis; 2009; 27(6):559-63. PubMed ID: 19390181
[TBL] [Abstract][Full Text] [Related]
35. Long-term virological outcome and resistance mutations at virological rebound in HIV-infected adults on protease inhibitor-sparing highly active antiretroviral therapy.
de la Rosa R; Ruíz-Mateos E; Rubio A; Abad MA; Vallejo A; Rivero L; Genebat M; Sánchez-Quijano A; Lissen E; Leal M
J Antimicrob Chemother; 2004 Jan; 53(1):95-101. PubMed ID: 14657091
[TBL] [Abstract][Full Text] [Related]
36. Observational study on HIV-infected subjects failing HAART receiving tenofovir plus didanosine as NRTI backbone.
Bongiovanni M; Gianotti N; Chiesa E; Nasta P; Cicconi P; Capetti A; di Biagio A; Matti A; Tirelli V; Marconi P; de Luca A; Mussini C; Gatti F; Zaccarelli M; Abeli C; Torti C; Antinori A; Castagna A; d'Arminio Monforte A
Infection; 2007 Dec; 35(6):451-6. PubMed ID: 18034204
[TBL] [Abstract][Full Text] [Related]
37. Declining prevalence of HIV-infected individuals at risk of transmitting drug-resistant HIV in Denmark during 1997-2004.
Lohse N; Obel N; Kronborg G; Jørgensen LB; Pedersen C; Larsen CS; Kvinesdal B; Sørensen HT; Gerstoft J
Antivir Ther; 2006; 11(5):591-600. PubMed ID: 16964827
[TBL] [Abstract][Full Text] [Related]
38. Impact on weight and height with the use of HAART in HIV-infected children.
Guillén S; Ramos JT; Resino R; Bellón JM; Muñoz MA
Pediatr Infect Dis J; 2007 Apr; 26(4):334-8. PubMed ID: 17414398
[TBL] [Abstract][Full Text] [Related]
39. The prevalence of metabolic syndrome in Danish patients with HIV infection: the effect of antiretroviral therapy.
Hansen BR; Petersen J; Haugaard SB; Madsbad S; Obel N; Suzuki Y; Andersen O
HIV Med; 2009 Jul; 10(6):378-87. PubMed ID: 19490178
[TBL] [Abstract][Full Text] [Related]
40. Clinical evidence of interaction between itraconazole and nonnucleoside reverse transcriptase inhibitors in HIV-infected patients with disseminated histoplasmosis.
Andrade RA; Evans RT; Hamill RJ; Zerai T; Giordano TP
Ann Pharmacother; 2009 May; 43(5):908-13. PubMed ID: 19401476
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
